NPY1R (neuropeptide Y receptor Y1) by Ruscica, M et al.









Atlas Genet Cytogenet Oncol Haematol. 2011; 15(3)  283 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
NPY1R (neuropeptide Y receptor Y1) 
Massimiliano Ruscica, Elena Dozio, Luca Passafaro, Paolo Magni 
Dipartimento di Endocrinologia, Fisiopatologia e Biologia Applicata, Universita degli Studi di Milano, Italy 
(MR, LP, PM), Dipartimento di Morfologia Umana e Scienze Biomediche "Citta Studi", Universita degli 
Studi di Milano, Italy (ED) 
 
Published in Atlas Database: June 2010 
Online updated version : http://AtlasGeneticsOncology.org/Genes/NPY1RID44260ch4q32.html 
DOI: 10.4267/2042/44985 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: NPYR 




History: The human NPY1R cDNA was cloned from a 
human brain cDNA library. The NPY1R was the first 
to be characterized, when the expression pattern of an 
orphan receptor was recognized to overlap with the 
distribution of NPY in brain. NPY receptors belong to 
the large superfamily of G-protein-coupled receptors. 
Many of these receptor genes lack introns, supporting 
the proposition that they were created via RNA-
mediated transpositional events. Differently from the 
other NPY receptor isoforms NPY1R is the only one 
containing a single 97-base pairs (bp) intron in the
coding region following the fifth transmembrane 
domain. 
Description 
A 14-kilobase pair (kb) region of genomic DNA 
encoding the human neuropeptide Y Y1-receptor gene 
including 3'- and 5'- flanking sequences is localized to 
chromosome 4. It encompasses 8632 bp of DNA 
(4q32.2) between 164245117 and 164253748 bp. The 
overall sequence of the gene consists of approximately 
10 kb. The genomic structure presents a 6-kb intron 
situated approximately 150 bp upstream of the start 
codon within the 5'-untranslated region (5'UTR), as 
well as a small intron within the coding region. 
The human NPY1R gene is divided into three exons: 
exon 1 (115 bp), exon 2 (850 bp), and exon 3 (1749 
bp). In particular, the NPY1R gene contains three 
alternative exon 1 sequences (80, 110, and 106 bp) 
located 6.4, 18.4, and 23.9 kb upstream of exon 2. Exon 
1A is located 6.4 kb upstream of exon 2; exon 1B was
found a further 12 kb upstream exon 1A, and exon 1C 
another 5.5 kb upstream of exon 1B. These alternative 
5' exons allow the regulation of tissue-specific 
expression of the receptor. The first 57 nucleotides of 
the 5'UTR of the human NPY1R mRNA are separated 
by a 6-kb intron from the second exon. The second 
intron 97 bp, containing an in-frame stop codon, is 
located at nucleotide 908 in the protein coding region 
after the fifth transmembrane domain between exon 2 
and 3. Moreover, as shown by Nakamura, mouse 
NPY1R gene contains an alternate exon 4 located over 
15 kb downstream of exon 3. 
Transcription 
The human cDNA encodes a protein of 384 amino-
acids (aa) in lenght that is preceded by approximately 
200 bp of 5'UTR sequence. 
 
Exon/intron structure and splice sites in the 5'UTR of the human NPY1R gene. 
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Figure A. Y1R affinity for various PP-family hormones and their C-terminal sequences. 




The NPY Y1 receptor subtype (Y1R) was the first to be 
cloned in the rat, and subsequently in human and 
mouse. This receptor is as conserved as its ligand 
(NPY) throughout evolution and mammalian and non-
mammalian species. The complete NPY1-36 molecule is 
necessary for NPY to bind to Y1R. Any proteolytic 
process leading to alterations in the NH2-terminal 
domain essentially abolishes the ability of NPY to bind 
to Y1R. Therefore, NH2-terminally truncated NPY 
fragments such as NPY2-36, or NPY3-36 have little or no 
affinity for the Y1R. Modification of COOH-terminal 
residues does not affect agonist binding. Thus, it has
been established that the NH2 terminus is essential for 
NPY to activate Y1R. The pharmacological profile of 
the Y1R is characterized by high affinity for NPY, 
PYY and the corresponding analogs containing Pro34 
and low affinity for the N-terminally truncated analogs 
and for PP. 
Description 
Y1R has seven putative transmembrane domains 
associated with G-protein (GPCR). In the N-terminal 
portion Y1R presents potential sites of glycosylation 
and in the second extracellular loop, four extracellular 
cysteines in position 33, 113, 198 and 296 which may 
form two disulfide bridges (Cys 33 and 296; Cys 133 
and 198). Phosphorylation sites are present in the 
intracellular domain (cysteine in the C-terminal portion 
at position 338). These cysteines may also explain the 
capability of palmitate residues to bind to the receptor. 
As observed for many GPCR, Y1R is internalized 
together with its ligand into endosomes and recycled to 
the cell surface within 60 minutes upon agonist 
stimulation. Moreover, Y1R is able to form 
homodimers. 
Expression 
The expression of the human NPY Y1 receptor has 
been studied extensively by using 
immunohistochemical methods, in situ hybridization 
experiments and reverse-transcription polymerase chain  
reaction (RT-PCR; mRNA detection). The human  
NPY1R is expressed in both central nervous system 
(i.e., cerebral cortex, thalamus and amigdala) and 
periphery (i.e., heart, kidneys, gastrointestinal tr ct, as 
well as blood vessels). 
Nervous system 
The NPY Y1R is widely distributed in the central 
nervous system. A study conducted on four normal 
human brains revealed that high levels of Y1R receptor 
mRNA were expressed in cortical areas and in the 
claustrum, while moderate levels were present in the 
nucleus accumbens, caudate nucleus, putamen, 
amygdaloid nuclei and arcuate and paraventricular 
nuclei of the hypothalamus. Moreover, a study 
conducted on prefrontal cortex of subjects affected by 
bipolar disorder, major depression, or schizophrenia 
revealed a progressive age-related decline in the 
expression of Y1R mRNA associated with a lack of 
coexpression with NPY neurons. Interestingly, there 
was no significant effect of suicide as a cause of death 
on Y1R mRNA expression levels. In fact, subjects with 
suicide as a cause of death tended to have higher Y1R 
mRNA expression levels, but these individuals were 
among the youngest ones (45 years old) in the 
population studied. 
Periphery 
Peripherally, Y1Rs are expressed mainly in arteries and 
veins, where they are associated with vasoconstriction 
and potentiation of other vasoconstrictors of neurogenic 
origin. Although limited, there is evidence of 
prejunctional Y1R inhibition of neurotransmitter 
release. Nonetheless, NPY Y1R is primarily located 
postjunctionally on vascular smooth muscle cells. 
1) Colon 
In vitro receptor autoradiography ([125I]PYY) 
performed on normal human colonic tissue obtained 
from nine patients showed that Y1R is distributed only 
in vessels. No measurable levels of subtype Y1 was 
identified in smooth muscle, mucosa, muscularis 
mucosae, as well as in lymphoid follicles, myoenteric 
and submucosal plexus. 
2) Heart 
A study conducted on 20-week old fetal human hearts 
showed that Y1R is present on right ventricular 
endocardial endothelial cells. In particular, it is h ghly  
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expressed at the level of the nucleus specifically at the 
perinucleoplasm and nuclear membrane levels, while 
lower levels were detected in the cytoplasm and the 
plasma membrane. 
3) Dental pulp 
NPY Y1R proteins were present in solubilized 
membrane preparations of both healthy and inflamed 
human gingival tissue by Western blotting. Major 
immunoreactive bands were detected at approximately 
55 kDa due to a glycosylated form of the native 
receptor protein. By using the SwissProt glycosylation 
prediction packages NetNGlyc and NetOGly, authors 
confirmed that the human Y1R has potential N- and O-
glycosylation sites. The expression of Y1R protein in 
both healthy and inflamed gingival tissue suggests that 
NPY could act via the Y1R to exert its tonic effects. 
Moreover, Y1R was expressed in human dental pulp 
with evidence of increased expression in carious 
compared with noncarious teeth. Y1R were localized to 
nerve fibres and inflammatory cells in the dental pulp 
of carious teeth. 
4) Achilles tendons 
Y1R is expressed in the tenocytes in the Achilles 
tendon. Specifically, Y1R is present within the smooth 
muscle of the blood vessel walls, but not in the 
endothelial layer of calcaneal tendons. 
5) Skin 
In human tissues, RT-PCR and immunocytochemistry 
studies suggested that Y1R is the primary receptor in 
human cutaneous circulation, supporting the findings 
that local non-noradrenergic mechanisms are entirely 
Y1R-based. Skin blood flow in humans is controlled 
through two branches of the sympathetic nervous 
system: a vasoconstrictor system and an active 
vasodilator system of uncertain neurotransmitter. In 
this context, NPY showed a vasoconstrictor effect in 
human subcutaneous arteries that had been dissected 
out of the abdominal regions from patients who 
underwent nonvascular disease surgeries (e.g., hernia). 
NPY decreased cutaneous blood flow via Y1R, with 
evidence for the additional involvement of 
postjunctional Y2R. This ability of NPY and Y1R to 
affect skin vascular conductance varies in accordance 
with relative innervations at specific sites. 
Localisation 
NPY Y1R is a seven transmembrane receptor which 
has all the characteristics of the GPCR family including 
potential glycosylation sites in the N-terminal porti n 
and in the second extra-cellular loop. 
Function 
NPY has been demonstrated to be involved in 
mitogenic pathways and stimulate cell proliferation via 
the Y1R. The activation of Y1R is generally associated 
with reduction of cAMP accumulation, increase of 
intracellular free calcium concentration ([Ca2+] i), and  
 
modulation of the MAPK pathway via several signaling 
molecules, including the protein kinase C (PKC). 
Y1R has been involved in several NPY-induced 
responses, such as activation of neuroendocrine axes, 
vasoconstriction, anxiolysis, as well as the stimulation 
of food intake. Moreover, Y1R mediates emotional 
behavior, stress response, and ethanol consumption. 
The prototype of NPY Y1R-mediated responses is 
vasoconstriction. Specifically, the physiological ro e of 
the Y1R subtype was demonstrated in mice lacking 
Y1R expression, which show no blood pressure 
response to NPY, but a normal response to 
norepinephrine. Y1R knockout mice have normal blood 
pressure, suggesting that the Y1R does not play a 
crucial role in maintaining blood pressure homeostasi  
in unstimulated conditions. However, Y1R has been 
also involved in other NPY-induced responses, such as 
stimulation of food intake and activation of 
neuroendocrine axes. In particular, Y1R and Y5R, both 
expressed in hypothalamic regions involved in the 
control of feeding, represent the most likely candidates 
for mediating the appetite stimulatory capacity of NPY. 
Mice lacking Y1R showed an increased body weight 
due to a low-energy expenditure rather than high-
energy intake. In fact, these mice had a decreased 
metabolic rate secondary to decreased locomotor 
activity and movement associated thermogenesis. 
Homology 
The human Y1R subtype shares closest aa identity with 
the Y4R subtype (42%) and the non-active, human 
form of the y6 subtype (51%). 
Mutations 
Note 
In 2004 Ramanathan described a case of autism in 
which a 19 megabase on chromosome 4q, spanning 
4q32 to 4q34, was detected. Being involved in the 
deletion, those genes which are abundantly expressed 
in the brain, Y1R and Y5R resulted implicated. In this 
context, being the neuroproliferative effect of NPY in 
the hippocampus mediated through the neuropeptide Y 
Y1R, the authors postulate that the effect of NPY on 
learning and memory may be mediated through NPY 
neurogenesis. 
Okahisa et al. described that genetic variants of 
rs7687423 of the NPY1R gene may alter the subjectiv 
effects of methamphetamine and result in susceptibility 
to dependence. Because NPY1R mRNA changes were 
observed in peripheral tissues and the brain in 
schizophrenia patients, these findings may also indicate 
that the NPY1R gene is involved in vulnerability to 
methamphetamine-induced psychosis because almost 
all of the analyzed subjects with methamphetamine 














NPY receptors are mainly expressed in specific 
endocrine tumors and epithelial malignancies as well as 
in embryonal tumors. In endocrine tumors, NPY 
receptors are present in steroid hormone producing 
tumors, namely adrenal cortical adenomas, carcinomas, 
ovarian granulosa cell tumors, Sertoli-Leydig cell 
tumors, and in catecholamine producing tumors, i.e. 
pheochromocytomas and paragangliomas. Based on 
pharmacological displacement experiments, in addition 
to tumor cells, intra- and peritumoral blood vessel 
express Y1Rs. The Y1R-expressing blood vessels are 
mainly small and medium-sized arteries. 
Prostate cancer 
Note 
Prostate cancer represents one of the most common 
malignant diseases among men in the Western world. It 
is initially androgen dependent and it may later 
progress to the androgen-independent stage, which is 
associated with a lack of efficacy of the available 
hormonal therapy. This tumoral progression appears to 
be promoted at least in part by several growth factors 
and neurohormones. Within this context, we showed 
that Y1R protein is expressed in three human prostate 
cancer cell lines (LNCaP -androgen dependent-, 
DU145 and PC3 -androgen independent-) and that 
NPY treatment reduced the proliferation of LNCaP and
DU145 cells and increased that of PC3 cells. 
Interestingly, the Y1R antagonist BIBP3226 abolished 
such effects, suggesting a mandatory role of Y1-R in 
this process. Moreover, these effects are associated 
with a clone-specific pattern of intracellular signali g 
activation, including a peculiar time-course of 
MAPK/ERK1/ERK2 phosphorylation (long-lasting in 
DU145 and transient in PC3 cells). 
Breast cancer 
Note 
Breast cancer accounts for almost 1/3 of all incident 
cases of cancer in women. Interestingly, the expression 
of NPY-Rs has been found in 85% of primary breast 
cancer in a series of 95 cases, and in 100% of lymph 
node metastases of receptor-positive primaries, where 
Y1R expression predominated and was often present in 
high density and great homogeneity. In normal breast 
tissue, however, Y1R was only found in a minority of 
the cases and concomitantly with Y2R, which seemed 
to be predominant in non-neoplastic breast. The 
neoplastic condition of breast tissue may thus induce a 
switch of expression from Y2R to Y1R.  
Moreover, a functional interplay between estrogen and
Y1R has been shown in a human breast cancer cell lin  
responsive to this steroid, where estrogen was found to 
increase Y1R expression, which in turn negatively 
regulated estrogen-stimulated cell proliferation. 
Pheochromocytoma and paraganglioma 
Note 
The frequency of NPY receptors (NPYRs) expression 
in pheochromocytomas and paragangliomas was found 
to be 35% and 61%, respectively. Both Y1R and Y2R 
are expressed, with a higher density of Y2R in 
paragangliomas than in pheochromocytomas, whereas 
the density of Y1R is comparably low in both tumor 
categories. NPYRs, mainly Y1R and Y5R, are also 
expressed in the Ewing's sarcoma family of tumors, 
other related neural crest-derived tumors, where 
activation of these receptors has been reported to 
regulate cell proliferation, as shown in the SK-N-MC 
cell line, an Ewing's sarcoma family of tumors 
expressing Y1R, where NPY has been shown to inhibit 
cell growth. 
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